Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This medication is a combination hormonal contraceptive (CHC) containing norethindrone acetate (a progestin) and ethinyl estradiol (an estrogen), along with ferrous fumarate (an iron supplement)[2][3]. It works primarily by preventing ovulation - stopping a woman's egg from fully developing each month so it can no longer accept sperm, thus preventing fertilization and pregnancy[2]. The ferrous fumarate tablets are included to provide iron supplementation during the hormone-free interval of the regimen[2][7]. The medication is typically taken in a specific sequence: active hormone tablets (containing norethindrone acetate and ethinyl estradiol) for 21-24 days, followed by ferrous fumarate tablets for the remaining days of a 28-day cycle[2][6][7]. This regimen helps maintain a regular menstrual cycle while providing continuous contraceptive protection. Besides preventing pregnancy, this medication may also be prescribed to treat acne[1][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ethinyl estradiol + norethindrone acetate + ferrous fumarate.